Blackman DJ, et al. - In this study including patients who underwent transcatheter aortic valve replacement (TAVR) from 2007 to 2011, researchers assessed the incidence of structural valve degeneration (SVD) 5 to 10 years after the procedure. They obtained demographic, procedural, and in-hospital outcome data for these patients from the UK TAVI (United Kingdom Transcatheter Aortic Valve Implantation) registry. This study included patients with echocardiographic data available both at baseline and ≥5 years post-TAVR; overall 241 patients (79.3 ± 7.5 years of age; 46% female) with paired post-procedure and late echocardiographic follow-up (median 5.8 years, range 5 to 10 years) were included. A self-expandable valve was used to treat 149 patients (64%) and a balloon-expandable valve to treat 80 patients (34.7%). Findings revealed excellent long-term transcatheter aortic valve function. Between 5 and 10 years post-implantation, SVD was not reported in 91% of patients. They reported <1% incidence of severe SVD and the occurrence of moderate SVD in 8.7% of patients.